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Abstract
p66Shc is shown to negatively regulate the life span in mice through reactive oxygen species (ROS)
production. Recent reports, however, revealed that p66Shc protein level is significantly elevated in
several human cancer tissues and growth-stimulated carcinoma cells, suggesting a mitogenic and
carcinogenic role for p66Shc. In this communication, we demonstrate for the first time that p66Shc
mediates androgenic growth signals in androgen-sensitive human prostate cancer cells through
mitochondrial ROS production. Growth stimulation of prostate cancer cells with 5?-
dihydrotestosterone (DHT) is accompanied by increased p66Shc level and ROS production, which
is abolished by antioxidant treatments. However, antioxidant treatments do not affect the
transcriptional activity of androgen receptor (AR) as observed by its inability to block DHT-induced
prostate-specific antigen expression, an AR-dependent correlate of prostate cancer progression.
Elevated expression of p66Shc by cDNA transfection increases the basal cell proliferation and, thus,
reduces additional DHT-induced cell proliferation. Furthermore, DHT increases the translocation of
p66Shc into mitochondria and its interaction with cytochrome c. Conversely, both redox-negative
p66Shc mutant (W134F), which is deficient in cytochrome c interaction, and p66Shc small interfering
RNA decrease DHT-induced cell proliferation. These results collectively reveal a novel role for
p66Shc–ROS pathway in androgen-induced prostate cancer cell proliferation and, thus, may play a
role in early prostate carcinogenesis.
Keywords
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Introduction
Shc (Src homolog and collagen homolog) proteins are widely known to serve as adapter
proteins in receptor protein tyrosine kinase signaling (Ravichandran, 2001). The three
isoforms, namely p66Shc, p52Shc and p46Shc, contain overlapping amino-acid sequences that
contribute to the SH2 domain at the C terminus and the phosphotyrosine-binding domain at
the N terminus, separated by a CH1 domain (Ravichandran, 2001). p66Shc has an additional
CH2 domain at its N terminus (Migliaccio et al., 1999). Upon tyrosine phosphorylation, the
SH2 domain of Shc protein binds to Grb2 to mediate SOS-associated Ras activation
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(Ravichandran, 2001). The phosphotyrosine-binding domain binds to the phosphorylated
tyrosine residues in receptor protein tyrosine kinases and functions in a manner similar to SH2
domain. The CH1 and CH2 domains are putative SH3-binding regions (Lotti et al., 1996).
p66Shc is expressed predominantly in the epithelial cells, although p52Shc and p46Shc
isoforms are ubiquitously expressed. Whereas p46Shc and a fraction of p66Shc localize to
mitochondria (Orsini et al., 2004; Ventura et al., 2004; Nemoto et al., 2006), p52Shc is
translocated to the plasma membrane from cytosol upon epidermal growth factor treatment
(Migliaccio et al., 1997). Shc isoforms, in general, are regulated by tyrosine phosphorylation
that transduce receptor protein tyrosine kinase signaling to downstream kinases, such as
mitogen-activated protein kinases, and concomitantly mediate cell proliferation
(Ravichandran, 2001). p66Shc is also phosphorylated at serine 36 in CH2 domain in response
to proapoptotic stress stimuli, such as hydrogen peroxide (H2O2), UV and Taxol (Migliaccio
et al., 1999; Yang and Horowitz, 2000).
The presence of the unique CH2 domain in p66Shc imparts functional divergence to the protein.
For example, unlike p52Shc, overexpression of p66Shc does not transform NIH3T3 mouse
fibroblast cells (Migliaccio et al., 1997) and may negatively regulate epidermal growth factor-
induced mitogen-activated protein kinase activation and c-myc promoter activity (Migliaccio
et al., 1997; Okada et al., 1997). In addition, p66Shc governs reactive oxygen species (ROS)
signaling and acts as a negative regulator of T-cell proliferation and survival (Migliaccio et
al., 1999; Pacini et al., 2004; Giorgio et al., 2005; Khanday et al., 2006). In particular, p66Shc
increases the intracellular oxidant levels by activating the mitochondrial electron transfer and
H2O2 production and/or by altering the mitochondrial metabolism in mouse embryo fibroblasts
cells (Giorgio et al., 2005; Nemoto et al., 2006). Alternatively, p66Shc may regulate ROS
production through SOS1-mediated Rac1 activation in these cells (Khanday et al., 2006).
Interestingly, p66Shc has been proposed as one of the lifespan determinants by virtue of its
apoptotic signaling in mouse models (Migliaccio et al., 1999), although its association with
human longevity remains to be established (Pandolfi et al., 2005).
Despite the fact that many studies imply p66Shc as a mediator of apoptosis, recent studies also
associate p66Shc with human epithelial cell proliferation and carcinogenesis. For example, in
ovarian carcinoma cell lines, p66Shc level positively correlates with ErbB-2 expression (Xie
and Hung, 1996). In breast cancer, p66Shc protein level is increased in cell lines with higher
metastatic ability and is elevated in lymph node-positive tumors (Jackson et al., 2000).
However, a negative correlation between p66Shc and tumorigenicity in breast cancer tissues
has been reported recently, and further studies are thus required to define its role in breast
carcinogenesis (Stevenson and Frackelton, 1998; Davol et al., 2003). Prostate carcinoma
tissues display higher p66Shc protein levels in the cancerous cells than the adjacent non-
cancerous cells (Lee et al., 2004a). In prostate cancer cell lines, p66Shc protein level positively
correlates with their growth rates (Lee et al., 2004a; Veeramani et al., 2005). Importantly,
growth stimulation of prostate, testis and breast cancer cell lines with steroid hormones is
accompanied by an increase in p66Shc protein level (Lee et al., 2004a), implying its function
in steroid-induced proliferation. Thus, the biological outcome of p66Shc signaling might be
diverse in different cell types.
Reactive oxygen species mediates different biological functions, including cell proliferation,
apoptosis, cell adhesion and migration. Studies in archival prostate cancer specimens display
a higher level of ROS in cancerous cells than the non-cancerous cells (Lim et al., 2005). In
parallel, highly tumorigenic sublines of LNCaP cells, C4-2 and C4-2B cells, have higher levels
of intracellular H2O2 than their parental cells (Lim et al., 2005). Additionally, antioxidant
supplements may reduce prostate cancer rates and large clinical trials using selenium and
vitamin E, such as SELECT, are currently being conducted (Klein et al., 2001). Thus, the role
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of ROS in prostate cancer growth and progression deserves attention. In this paper, we report
for the first time that p66Shc mediates androgenic proliferation signals, but not prostate-
specific antigen (PSA) expression or secretion, in androgen receptor (AR)-positive prostate
cancer cells through ROS production. Our data together may suggest a functional role for
p66Shc in androgen-induced prostate carcinogenesis.
Results
Androgen requires ROS production for growth stimulation of prostate cancer cells
To investigate whether androgen-induced ROS production is required for androgen-stimulated
prostate cancer cell proliferation, we treated androgen-sensitive LNCaP prostate cancer cells
with 10 nM 5?-dihydrotestosterone (DHT) in the presence or absence of antioxidants, N-acetyl
cysteine (NAC) and vitamin E succinate (VES). In the absence of antioxidants, DHT stimulated
cell growth by approximately 40–50% after 48 h of treatment; as NAC significantly abolished
DHT-induced cell proliferation in a dose-dependent manner (r = ?0.988; P<0.05; Figure 1a).
Correspondingly, DHT-induced increase in Cyclin D1 level, a key regulator of cell cycle
progression, was blocked by NAC (Figure 1b, lanes 5 vs 6, 7 and 8). The inhibition of cell
proliferation was further confirmed by bromodeoxyuridine assay that NAC treatment
significantly reduced DHT-induced DNA biosynthesis in LNCaP cells (P<0.01; Figure 1c).
Similarly, treatment with VES significantly decreased DHT-induced LNCaP cell proliferation
(P<0.01; Figure 1d). Parallel observations were obtained with MDA PCa2b cells that DHT-
induced growth stimulation was significantly abolished by VES (P<0.01; Figure 1e) and NAC
(data not shown). Collectively, these data suggested that ROS production is required for DHT-
induced prostate cancer cell proliferation.
Consistent with our hypothesis that ROS can mediate cell proliferation, treatment of LNCaP
cells with 10 ?M H2O2, a physiologically achievable concentration, increased cell proliferation
(Figure 2a) and Cyclin D1 protein levels (Figure 2b, lanes 1 vs 3, 4 and 5) similar to that of 10
nM DHT following a dose-response over a period of 48 h treatment. Furthermore, H2O2-
induced cell proliferation showed a time-dependent increase (data not shown). Moreover,
overexpression of Mn-superoxide dismutase (Mn-SOD), a mitochondrial enzyme that converts
superoxide to H2O2, upregulated proliferation and Cyclin D1 level in LNCaP cells, similar to
10 nM DHT (Figures 2c and d, lanes 1 vs 3). Taken together, the data highlighted the role of
ROS in growth stimulation by DHT in prostate cancer cells.
Interestingly, ROS did not have any appreciable effect on the expression and secretion of PSA.
As shown in Figure 1b, treatment with NAC neither blocked DHT-induced increase in cellular
PSA nor its secretion. Similarly, neither H2O2 treatment nor MnSOD overexpression in LNCaP
cells had any stimulatory effect on PSA expression and secretion (Figures 2b and d).
Furthermore, none of these agents had any detectable effect on AR protein level in those treated
cells (Figures 1b and 2b). As PSA expression and secretion are dependent on AR transcriptional
activity, the data signified the specificity of ROS in activating DHT-induced cell proliferation,
but not AR-dependent gene expression.
p66Shc regulates DHT-induced proliferation in prostate cancer cells
Previous studies indicated that p66Shc, which increases intracellular ROS levels, is elevated
in DHT-treated prostate cancer cells (Lee et al., 2004a; Giorgio et al., 2005; Veeramani et
al., 2005; Khanday et al., 2006). In parallel, kinetic analyses revealed that p66Shc protein levels
in DHT-treated cells are higher than control cells (Figure 3a). Furthermore, semiquantitative
analyses of the blots indicated a significantly higher level of p66Shc protein from 8 h of DHT
treatment (P<0.05) (Supplementary Figure 1) prior to increase in ROS production (16 h), as
indicated by an dichlorofluorescein diacetate (DCF-DA) fluorescence (Figure 3b), and the
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stimulation of cell proliferation, as indicated by the increase in Cyclin D1 level (24 h) (Figure
3a), the percentage of cells at S-phase (24 h) (Figure 3c) and cell number (48 h) (Figure 3d).
The role of p66Shc in androgen-stimulated cell proliferation was further evaluated by the
elevated expression of p66Shc through wild-type cDNA transfection in LNCaP cells. Transient
transfection of p66Shc cDNA alone led to a significant upregulation of cell proliferation
(P<0.01; Figure 4a) and Cyclin D1 expression (Figure 4b, lanes 1 vs 3) equivalent to that of
DHT treatment, whereas the addition of DHT to these cells did not have a significant added
effect on their proliferation (P>0.05). In addition, stable subclones of LNCaP cells with
elevated expression of p66Shc (S-32 and S-36) showed increased cell proliferation (Figure 4c)
and Cyclin D1 protein levels (Figure 4d, lanes 1 vs 2 and 3) as compared to the vector-alone
transfected control cells (V-1). Similarly, increased expression of p66Shc increased MDA
PCa2b cell proliferation (Figure 4e).
p66Shc regulates ROS generation in prostate cancer cells
To determine whether p66Shc induces cell proliferation through ROS production, we measured
the intracellular ROS levels in cells with elevated expression of p66Shc. As shown in Figure
5a, elevated expression of p66Shc by transient transfection significantly increased the
intracellular ROS level, similar to DHT treatment in LNCaP cells. Treatment of these p66Shc
cDNA-transfected LNCaP cells with antioxidants, NAC and VES, decreased their proliferation
(Figure 5b). In addition, ectopic expression of glutathione peroxidase 1, an antioxidant
mitochondrial enzyme, in p66Shc stable subclone cells significantly decreased their rapid
growth (Figure 5c). These data together indicated the requirement of ROS production in
p66Shc-stimulated cell proliferation in prostate cancer cells.
DHT promotes the interaction between p66Shc and cytochrome c, a mitochondrial protein
In mouse embryonic fibroblast cells, a fraction of p66Shc protein localizes to mitochondria
and interacts with cytochrome c (Cyt c) in the electron transport chain to generate ROS (Orsini
et al., 2004; Giorgio et al., 2005; Nemoto et al., 2006). Our data revealed that DHT increased
the translocation of p66Shc into mitochondria of LNCaP cells by 16 h after DHT treatment
(Figure 6a, lanes 6 vs 7), which correlates with the increase in ROS production (Figure 3b).
Interestingly, even though the total p66Shc protein level in the total lysate was elevated by 8
h, the mitochondrial translocation did not occur at 8 h (Figure 6a, lanes 2 vs 3). Co-
immunoprecipitation analysis by using anti-Myc antibody to pull-down overexpressed Myc-
tagged p66Shc revealed that DHT increased the interaction between exogenous p66Shc and
Cyt c in LNCaP cells at 16 h time point (Figure 6b, upper panel, lanes 7 vs 8). Similarly, DHT
increased the interaction between Cyt c and endogenous p66Shc protein as shown in Cyt c
pull-down assay (Figure 6b, lower panel, lanes 5 vs 6).
To further establish the requirement of ROS production through p66Shc–Cyt c interaction in
DHT-induced cell proliferation, we ectopically expressed a mutant p66Shc (W134F), which
lacks the ability to interact with Cyt c (Giorgio et al., 2005), in LNCaP cells in the presence or
absence of DHT. Cells that were transfected with the wild-type p66Shc or empty vector in the
presence or absence of DHT served as controls. DCF-DA analyses showed that only the wild-
type p66Shc, but not its redox-negative mutant, increased the ROS production (data not shown).
Unlike the wild-type p66Shc, the W134F mutant did not increase the basal level of cell
proliferation (Figure 7a). Interestingly, the W134F mutant significantly abolished DHT-
stimulated cell proliferation in these cells (Figure 7a). In parallel, DHT treatment and wild-
type p66Shc transfection increased Cyclin D1 level, whereas W134F mutant blocked the DHT-
induced increase in Cyclin D1 expression (Figure 7b, lanes 2, 4 vs 6). Similar results were also
observed in MDA PCa2b cells that DHT-induced cell proliferation was significantly blocked
by W134F mutant of p66Shc (Figure 7c).
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To further validate the requirement of p66Shc in DHT-stimulated cell proliferation, we
analysed the proliferation of p66Shc knocked-down LNCaP cells in response to DHT. Notably,
DHT-induced cell proliferation and Cyclin D1 level were significantly decreased in p66Shc
knocked-down LNCaP cells as compared to the control cells (P<0.01; Figures 7d and e, lanes
3 vs 4). Furthermore, ectopic expression of WT p66Shc into endogenous p66Shc-knocked-
down cells restored their increased basal cell proliferation and ROS production similar to that
of DHT treatment; whereas ectopic expression of W134F in these cells failed to significantly
increase basal as well as DHT-induced cell proliferation and ROS production (Supplementary
Figure 2). Taken together, these data indicated that DHT upregulates ROS production by
increasing the interaction of p66Shc with Cyt c that leads to increased prostate cancer cell
proliferation.
Discussion
Androgens trigger diverse biological effects in various cells, including cell proliferation and
differentiation, through differential molecular signals that require further elucidation. In
androgen-sensitive prostate cancer cells, activated AR upregulates cell proliferation and gene
expression, such as PSA, an indicator for AR transcriptional activity and a surrogate marker
for clinical cancer progression. In this communication, we describe a novel redox pathway by
which AR specifically activates cell proliferation, distinct from PSA expression and secretion.
Our data clearly show that androgenic treatment of androgen-sensitive prostate cancer cells
leads to increased ROS production, which in turn stimulates cell proliferation (Figures 1 and
3). Evidently, antioxidants abolish DHT-induced cell proliferation (Figure 1). However,
treatment with antioxidants does not affect DHT-induced PSA expression and secretion,
indicating that AR transcriptional activity does not require DHT-induced ROS (Figure 1b).
Interestingly, DHT-induced cell proliferation requires the redox activity of p66Shc. For
example, overexpression of redox-negative p66Shc mutant (W134F) or knockdown of
endogenous p66Shc abolishes DHT-induced proliferation (Figure 7). Nevertheless,
knockdown of p66Shc does not affect the ability of DHT-AR to increase PSA level (data not
shown). To the best of our knowledge, this is the first report that p66Shc–ROS pathway
mediates early androgenic cell proliferation in androgen-sensitive prostate cancer cells, which
is independent of AR-dependent gene expression, such as PSA.
Data obtained from this study, thus, provide a molecular explanation for the clinical
observations on increased p66Shc and ROS production in archival prostate cancer specimens
(Lee et al., 2004a; Lim et al., 2005). In parallel, increased levels of H2O2-producing enzymes,
such as Nox1 and SOD, are also noticed in prostate cancer specimens (Kuruma et al., 2005;
Lim et al., 2005). These observations signify the possible role of redox signaling in prostate
cancer progression. Furthermore, the promotion of prostate cancer cell proliferation by
p66Shc–ROS pathway, but not PSA secretion, could explain an important clinical phenomenon
observed in a subgroup of prostate cancer patients who do not show elevated PSA levels.
Present data further explore a novel mechanism by which steroid hormones contribute to higher
ROS levels in prostate cancer cells. As evidenced, p66Shc protein level is increased in DHT-
treated prostate cancer cells (Figure 3; Lee et al., 2004a; Veeramani et al., 2005). Our kinetic
analysis indicated a causal relationship between p66Shc and ROS production as well as cell
proliferation during DHT action in prostate cancer cells (Figure 3). AR is apparently required
for DHT effect on p66Shc because Casodex, an antiandrogen, abolished the upregulatory effect
of DHT on p66Shc (Lee et al., 2004a). Interestingly, our immunoblot data revealed that the
observed increase in p66Shc levels in DHT-treated cells at any given time point is, in part, due
to the rapid decline of p66Shc levels in control cells (Figure 3a). Thus, it is apparent that p66Shc
protein is degraded over time during androgen deprivation in prostate cancer cells, whereas its
stability is increased in DHT-treated cells.
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Previous studies indicated that p53 increases p66Shc protein stability in mouse embryonic
fibroblast cells (Trinei et al., 2002). However, our study showed that DHT treatment did not
increase p53 protein levels (Supplementary Figure 3); whereas DHT increased p66Shc protein
levels (Figure 3a). Furthermore, p53 is a tumor suppressor and is either downregulated or
mutated in various cancers (Bourdon, 2007), whereas p66Shc protein level is elevated in
several cancers, including prostate cancer (Lee et al., 2004a; Park et al., 2005; Grossman et
al., 2007). These data together imply that DHT–AR complex might affect the stability of
p66Shc protein in DHT-treated cells in a p53-independent manner. Further studies are required
on the role of AR in p66Shc protein stability.
p66Shc was initially reported as a proapoptotic molecule, as shown in mouse embryo
fibroblasts (Migliaccio et al., 1999; Giorgio et al., 2005; Khanday et al., 2006). However,
several lines of evidence suggest that p66Shc might mediate growth signals in epithelial cells
and carcinomas (Xie and Hung; 1996; Lee et al., 2004a; Park et al., 2005; Veeramani et al.,
2005; Grossman et al., 2007). In our study, elevated expression of p66Shc in androgen-
sensitive prostate cancer cells did not induce significant cell death as clearly evidenced by cell
counting (Figure 4), intracellular proapoptotic Bax protein levels and subG1 DNA content
(Veeramani S and Lin MF, unpublished observations). Thus, further studies are needed to
determine whether the physical interaction between p66Shc and Cyt c might hamper apoptotic
signaling by preventing Cyt c from leaking into cytoplasm in epithelial cells. Altogether, these
observations imply that p66Shc is at the crossroads of proapoptotic and proliferative signal
pathways and transduces divergent signals in different cell types that result in distinct biological
outcomes.
Even though p66Shc protein does not contain a putative mitochondrial targeting sequence,
about 10% of total cellular p66Shc localizes in mitochondrial inner membrane, where it
regulates ROS production, through its interaction with Cyt c (Giorgio et al., 2005). Our data
reveal that DHT increases the mitochondrial translocation of p66Shc (Figure 6a) and its
subsequent interaction with Cyt c to produce ROS (Figure 6b). Furthermore, kinetic analysis
on the mitochondrial translocation of p66Shc indicated that although the p66Shc total protein
level is significantly elevated at 8 h after DHT treatment, mitochondrial translocation occurs
only at 16 h, the subsequent time point analysed (Figures 3a and 6a), which coincides with the
increase in Cyt c interaction and ROS production (Figures 3b and 6b). Importantly, W134F
mutant, which lacks Cyt c-binding and ROS generating ability, abolishes DHT-induced cell
proliferation (Figures 7a and c). These data signify the role of mitochondrial Cyt c oxidation
and ROS production in androgen-stimulated cell proliferation in androgen-sensitive prostate
cancer cells. In parallel, DHT treatment has been shown to increase the mitochondrial activity
in AR-positive prostate cancer cells (Ripple et al., 1997). Nevertheless, the involvement of
other redox proteins in DHT-induced ROS production cannot be ruled out in this study.
Serine-36 phosphorylation followed by prolyl isomerization of p66Shc is proposed to be
necessary for its mitochondrial translocation in mouse embryonic fibroblast cells treated with
proapoptotic concentrations of H2O2 (Pinton et al., 2007). We analysed whether growth
stimulants, such as DHT, would also employ a similar mechanism in prostate cancer epithelial
cells. Nevertheless, under our experimental conditions, DHT decreased the serine-36
phosphorylation level of p66Shc in a time-dependent manner (Supplementary Figure 4a and
b). Furthermore, ectopic expression of S36A mutant of p66Shc did not decrease DHT-induced
cell proliferation in these cells (Supplementary Figure 4c). We propose that DHT-induced
mitochondrial translocation of p66Shc and subsequent cell growth induction are mediated by
a serine-36 phosphorylation-independent mechanism. Furthermore, semiquantification
analysis of immunoblots indicated that p66Shc level at 16 h of DHT treatment in total lysate
increased by approximately 40%; whereas the increase in the mitochondrial fraction of DHT-
treated cells at the same time point was about 200%, indicating that there is a net increase in
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the translocation of p66Shc (Supplementary Figure 5). Thus, it is apparent that there are
differential mechanisms regulating p66Shc signaling depending on the specific cell type
(mouse embryonic fibroblast vs prostate epithelial cells) and the type of stimulus (apoptosis
vs proliferation) involved. Further studies are required to identify the mechanism of DHT-
induced mitochondrial translocation of p66Shc protein.
In summary, our data reveal a novel signaling pathway regulating androgenic cell proliferation
that involves p66Shc and ROS production; although, the androgenic stimulation of PSA
expression and secretion, a marker for AR activation, is not mediated by the p66Shc–ROS
pathway. As shown in Figure 8, as an early event of non-genomic signaling in androgen action,
DHT-bound AR increases p66Shc protein levels and its translocation into mitochondria, where
p66Shc activates the ROS producing machinery in mitochondria. Increased ROS levels could
activate mitogenic signaling pathways, for example, activation of tyrosine kinases through
inactivation of their inhibitory phosphatases, which promote cell cycle progression through
Cyclin D1 and cell proliferation. The observations that overexpression of p66Shc has a positive
effect on the proliferation of AR-positive cells have potential clinical implications because
most of the early as well as the advanced prostate cancer cells express functional AR. The
observation that p66Shc level is higher in archival cancer specimens warrants further studies
to define the role of p66Shc in prostate cancer progression.
Materials and methods
Reagents, cDNA and antibodies
Fetal bovine serum (FBS), gentamicin, L-glutamine, RPMI 1640 medium and DCF-DA were
obtained from Invitrogen (Carlsbad, CA, USA). Charcoal/dextran-treated FBS was purchased
from HyClone (Logan, UT, USA). Myc-tagged wild-type p66Shc cDNA was constructed in
pcDNA3.1 vector (Veeramani et al., 2005). Mutant p66Shc cDNA, whose tryptophan 134 was
mutated to phenylalanine (W134F), was created by site-directed mutagenesis and confirmed
by DNA sequencing. Full-length cDNA encoding Mn-SOD was a kind gift from Dr Larry W
Oberley at University of Iowa College of Medicine (Iowa City, IA, USA). Plasmid encoding
an enhanced cyan fluorescent protein (pECFP-N1) was a kind gift from Dr Parmender P Mehta,
University of Nebraska Medical Center (Omaha, NE, USA). Full-length glutathione peroxidase
1 cDNA was purchased from OriGene Technologies (Rockville, MD, USA). Polyclonal
antibodies recognizing all three Shc isoforms, glutathione peroxidase 1, Mn-SOD, Cyclin D1
were from Santa Cruz Biotechnology Ltd (Santa Cruz, CA, USA). Anti-?-actin antibody, NAC
and VES were from Sigma (St Louis, MO, USA). All the other reagents and chemicals used
in this study were as described previously (Lin et al., 1998; Meng and Lin, 1998; Lee et al.,
2004a, b; Veeramani et al., 2005).
Cell lines
Androgen-sensitive human prostate cancer cell lines, LNCaP-FGC (Horoszewicz et al.,
1983) and MDA PCa2b (Navone et al., 1997), were purchased from the American Type Culture
Collection (Rockville, MD, USA). LNCaP cells were routinely maintained in phenol red-
positive RPMI 1640 medium supplemented with 5% FBS (v/v), 2 mM glutamine and 50 ?g/
ml gentamicin (Lin et al., 1998). For DHT treatment, LNCaP cells, with passage number less
than 35 (Lin et al., 1998) were steroid starved for 48 h in steroid-reduced medium, that is,
phenol red-free RPMI 1640 medium containing 5% charcoal/dextran-treated FBS, 2 mM
glutamine and 50 ?g/ml gentamicin. Cells were then exposed to DHT (10 nM) and harvested
after various periods of time, as indicated in each experiment. MDA PCa2b cells were cultured
in BRFF-HPC1 medium containing 20% FBS, 2 mM glutamine and 50 ?g/ml gentamicin (Lee
et al., 2004a; Veeramani et al., 2005). For steroid-reduced conditions, BRFF-BMZERO
medium containing 15% charcoal/dextran-treated FBS was used. For cell growth experiments,
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the cells were trypsinized and counted in a Z1 model Coulter Counter (Coulter Corporation,
Miami, FL, USA).
Transfection
For transient transfection experiments, LNCaP cells were plated at a density of 1 × 104 cells
per cm2 and transfected using Lipofectamine and Plus reagents. Four hours after transfection,
the cells were fed with RPMI media containing 10% FBS for 24 h. The cells were then steroid
starved for 48 h before they were treated with 10 nM DHT. Stable subclones of LNCaP cells
overexpressing p66Shc were derived as described (Veeramani et al., 2005). MDA PCa2b cells
were plated at a density of 4 × 104 cells/cm2 and transfected using Lipofectamine 2000 in the
presence of 5% FBS.
Immunoblotting
The protocols for immunoblotting were as described previously (Lin et al., 1998; Meng and
Lin, 1998). Briefly, subconfluent cells were scraped and were rinsed with ice-cold 20 mM
HEPES-buffered saline, pH 7.0. Cell pellet was lysed in ice-cold high-stringent cell lysis buffer
containing protease and phosphatase inhibitors, spun at 200 × g for 10 min. Medium samples
were collected and spun at 200 × g for 10 min. ?-actin protein levels were used as loading
controls for cell lysates. For medium samples, membrane was stained with Coomassie blue
R250 to confirm equal loading of samples.
Co-immunoprecipitation
Co-immunoprecipitation was performed using the ExactaCruz kit (Santa Cruz Biotech) as per
the recommended protocols. Briefly, 10 ?g of anti-Myc or anti-Cyt c antibody (Upstate, Lake
Placid, NY, USA) was incubated with mouse IP matrix for 2 h at 4 °C and then washed with
IP lysis buffer (20 mM HEPES, pH 7.0, 150mM NaCl, 1% NP-40, 1 mM EDTA, 10 mM
MgCl2 and 10% glycerol containing protease and phosphatase inhibitors) for three times. Cell
lysate of 1 mg was mixed with antibody-mouse IP matrix complex and incubated for 2 h at 4
°C. The immune complexes were washed three times with IP lysis buffer and the pellet was
boiled in 2 × Laemmli sample buffer and subjected to immunoblotting.
ROS measurement
Intracellular H2O2 level was estimated by DCF-DA assay (Giorgio et al., 2005; Khanday et
al., 2006). Briefly, the cells were rinsed in Krebs-Ringer buffer and exposed to 20 ?M DCF-
DA in the dark for 15 min at 37 °C. Subsequently, the cells were trypsinized and resuspended
in Krebs-Ringer buffer. Intracellular fluorescence was quantified by flow cytometry (Becton-
Dickinson Franklin Lakes, NJ, USA). Relative fluorescence was plotted as ratio to the control
cells. In transient transfection experiments, the cells were co-transfected with pECFP-N1 and
p66Shc cDNA. After incubation with DCF-DA, ROS levels were measured in ECFP-positive
cells using BD LSR II flow cytometer (Becton-Dickinson).
Subcellular fractionation
Subfractionation of LNCaP cells were carried out as described (Giorgio et al., 2005). Briefly,
subconfluent cells were scraped and cell pellet was homogenized in ice-cold MTC buffer
containing 0.25 m sucrose using a Dounce glass homogenizer. Homogenized cells were
centrifuged to pellet down nucleus and cell debris (700 × g). The supernatant was spun at 8000
× g for 15 min to pellet mitochondria. Finally, the lysate was spun at 15 000 × g and the clear
supernatant representing cytosolic fraction was isolated. Total cell and mitochondrial pellets
were lysed in ice-cold high-stringent lysis buffer. Equal amount of total, mitochondrial and
cytosolic proteins were subjected to immunoblotting as described earlier.
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RNA silencing
To knockdown p66Shc expression, pSUP-p66, a plasmid-based small interfering RNA system
targeted against the CH2 region of p66Shc, was used (Veeramani et al., 2005). Transfection
of pSUP-p66 was performed as described for cDNA transfection.
Statistical analysis
Each experiment was performed in duplicates, repeated 2–3 times and the mean and standard
error values were calculated. The significance of difference (P-value) was calculated using
independent t-test and the P-value less than 0.05 was considered as significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Requirement of reactive oxygen species (ROS) production in dihydrotestosterone (DHT)-
induced prostate cancer cell proliferation. (a) LNCaP cells were plated at a density of 1 ×
104 cells per cm2 in regular medium. Seventy-two hours later, cells were steroid starved using
steroid-reduced medium for 48 h. Cells were then treated with 10 nM DHT in the presence or
absence of different doses of N-acetyl cysteine (NAC) (0–10mM) for 48 h. Cell growth was
determined by cell counting (*P<0.01; r = ?0.988, P<0.05). (b) Immunoblot analysis of Cyclin
D1, androgen receptor (AR), prostate-specific antigen (PSA) levels in cell lysates (cPSA) and
secreted PSA in condition medium (sPSA) was performed in DHT-treated LNCaP cells in the
presence or absence of NAC (0–10 mM). (c) DHT-treated LNCaP cells in the presence or
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absence of 10mM NAC were immunostained for bromodeoxyuridine (BrdU) incorporation,
which showed inhibition of DHT-induced BrdU incorporation by antioxidant (*P<0.01). (d)
LNCaP cell growth induced by 10 nM DHT was abolished by 10 ?M vitamin E succinate
(VES), another antioxidant (*P<0.01). (e) MDA PCa2b cells were plated at a density of 4 ×
104 cells per cm2 and were allowed to attach for 3 days. Cells were then starved with steroid-
reduced medium, as mentioned in the Methods section, for 48 h. Cells were treated with DHT
in the presence or absence of VES (10 ?M) and cell growth was measured by cell counting
after 72 h (*P<0.01).
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Figure 2.
Stimulation of proliferation of prostate cancer cells by increased intracellular reactive oxygen
species (ROS) levels. (a) LNCaP cells plated at a density of 1 × 104 cells per cm2 were steroid
starved for 48 h and, later, were treated with different doses of H2O2 (0–20 ?m) or 10 nM
dihydrotestosterone (DHT) for 48 h. Cell growth was determined by cell counting (*P<0.05;
**P<0.01). (b) Immunoblot analysis was performed for Cyclin D1, androgen receptor (AR),
prostate-specific antigen (PSA) levels in cell lysates (cPSA) and secreted PSA levels in
conditioned medium (sPSA) in LNCaP cells treated with different doses of H2O2 (0–20 ?M)
or 10 nM DHT. (c) LNCaP cells were plated at a density of 1 × 104 cells per cm2 for 48 h and
transfected with superoxide dismutase (SOD) cDNA. Control cells were transfected with
empty vector. Cells were steroid starved for 48 h and then were treated with ethanol or 10 nM
DHT. Cells were counted 48 h post-treatment (*P<0.05). (d) Immunoblot analysis was
performed in SOD-overexpressed LNCaP cells for Cyclin D1 and PSA levels in cell lysates.
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Figure 3.
Elevation of p66Shc prior to reactive oxygen species (ROS) production and cell growth
induction in dihydrotestosterone (DHT)-treated LNCaP cells. LNCaP cells were plated and
steroid starved for 48 h. Cells were then treated with 10 nM DHT and control cells were treated
with equal volume of ethanol. Cells were harvested at specific time periods and were analysed
for (a) Shc isoforms, Cyclin D1 and secreted prostate-specific antigen (sPSA) protein levels
by immunoblotting, (b) ROS production using DCF-DA analysis (*P<0.05), (c) cell cycle
analysis (*P<0.01) by flow cytometry and (d) cell growth analysis (*P<0.01) by cell counting.
Veeramani et al. Page 15
Oncogene. Author manuscript; available in PMC 2009 November 12.
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t
Figure 4.
Stimulation of cell proliferation by overexpression of p66Shc in prostate cancer cells. (a)
LNCaP cells were plated at a cell density of 1 × 104 cells per cm2 for 48 h and then transfected
with p66Shc wild-type cDNA. Control cells were transfected with empty vector. Transfected
cells were starved for 48 h and then treated with ethanol or 10 nM dihydrotestosterone (DHT)
for 48 h. Cell growth was analysed by cell counting (*P<0.01). (b) Immunoblot analysis was
performed for Cyclin D1 protein levels in p66Shc-overexpressed LNCaP cells (lanes 3 and 4)
and vector-alone transfected control cells (lanes 1 and 2), in the presence or absence of DHT.
(c) LNCaP cells stably transfected with p66Shc cDNA (S-32 and S-36) and with vector-alone
cells (V-1) were plated at a density of 8 × 103 cells per cm2 in regular medium for 3 days. Cells
were steroid starved for 48 h and then replenished with steroid-reduced medium. One set of
the cells were trypsinized and counted 3 days later. The other set of cells were fed with fresh
steroid-reduced medium and trypsinized at day 6 (*P<0.05). (d) Immunoblot analysis was
performed for Cyclin D1 and p66Shc levels in p66Shc stable subclone cells that were harvested
at day 3 of cell growth experiment. (e) MDA PCa2b cells were plated at a cell density of 4 ×
104 cells per cm2 for 48 h and were transfected with p66Shc wild-type cDNA or empty vector.
Cells were steroid starved for 48 h and then treated with 10 nM DHT. Cell growth was analysed
72 h after DHT treatment by cell counting (*P<0.05).
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Figure 5.
Generation of reactive oxygen species (ROS) in p66Shc overexpressed prostate cancer cells.
(a) LNCaP cells were plated at a density of 1 × 104 cells per cm2 and co-transfected with
p66Shc cDNA and enhanced cyan fluorescent protein (ECFP) cDNA. Control cells were
transfected with empty vector and ECFP cDNA. After 48 h of steroid starvation, cells were
treated with 10 nM dihydrotestosterone (DHT) or ethanol. DCF-DA assay was performed with
20 ?M of DCF-DA in dimethyl sulfoxide for 15 min. Green DCF-DA fluorescence was
measured in ECFP-positive cells by flow cytometry (*P<0.05). (b) LNCaP cells were
transiently transfected as above and were steroid starved for 48 h. Cells were then treated with
10 mM N-acetyl cysteine (NAC) or 10 ?M vitamin E succinate (VES) for additional 48 h and
cell growth was measured (*P<0.05). (c) LNCaP cells stably transfected with p66Shc cDNA
(S-32 and S-36) and with vector-alone cells (V-1) were plated at a density of 1 × 104 cells per
cm2 and were transfected with different amounts of cDNA encoding glutathione peroxidase 1
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(pGPx1). Cells were then steroid starved for 48 h and then replenished with steroid-reduced
medium. Forty-eight hours later cells were trypsinized and counted (*P<0.05, **P<0.01).
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Figure 6.
Translocation of p66Shc into mitochondria and its interaction with cytochrome c (Cyt c) in
dihydrotestosterone (DHT)-treated LNCaP cells. (a) LNCaP cells were treated with 10 nM
DHT and were subfractionated after 8 and 16 h after treatment as described (Giorgio et al.,
2005). Total cell lysate (total) and the subfractionated mitochondrial (Mito) and cytosolic
(Cyto) fractions were analysed by immunoblotting for p66Shc compartmentalization. Cyt c
was used as a mitochondria-specific marker and Pyk2, a cytoplasmic tyrosine kinase, was used
a cytosol-specific marker. (b) LNCaP cells were transiently transfected with Myc-tagged
p66Shc wild-type cDNA or empty vector and steroid starved for 48 h. Cells were the treated
with 10 nM DHT for 16 h. Co-immunoprecipitation assay was performed with anti-Myc
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antibody (as mentioned in the Materials and methods section) to analyse the interaction
between Cyt c and exogenous p66Shc. Interaction was compared between p66Shc-
overexpressed cells, which express both endogenous and exogenous p66Shc, in the presence
or absence of DHT (upper panel, lanes 7 vs 8). To analyse the endogenous protein interaction,
anti-Cyt c antibody was used to pull-down Cyt c and the membrane was probed was anti-Shc
antibody. Interaction was compared between empty vector-transfected cells with or without
DHT, which express only endogenous p66Shc (lower panel, lanes 5 vs 6).
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Figure 7.
Requirement of reactive oxygen species (ROS) production by p66Shc in dihydrotestosterone
(DHT)-induced LNCaP cell proliferation. (a) LNCaP cells were transfected with wild-type
p66Shc cDNA (WT) or W134F mutant or empty vector alone (pcDNA). Cells were steroid
starved for 48 h and treated with 10 nM DHT as described above. Cells were trypsinized and
counted after 48 h of treatment (*P<0.05). (b) Immunoblot analysis was performed for Cyclin
D1 level in LNCaP cells transiently overexpressing WT or W134F mutant in the presence or
absence of DHT, as mentioned above. (c) MDA PCa2b cells were plated at 4 × 104 cells per
cm2 and transiently transfected WT and W134F mutant of p66Shc and treated with DHT, as
mentioned earlier. Seventy-two hours after DHT treatment cells were trypsinized and counted
(*P<0.05). (d) Small interfering RNA (siRNA) fragments specific to p66Shc cloned in
pSUPER vector (pSUP-p66) was transiently transfected into LNCaP cells as per the conditions
mentioned for cDNA transfection. Cells were treated with DHT for 48 h and cell growth was
measured (*P<0.01). (e) Immunoblot analysis was performed for Cyclin D1 levels in LNCaP
cells transiently transfected with p66Shc-specific siRNA (pSUP-p66).
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Figure 8.
A schematic representation of the p66Shc pathway in androgen action on prostate cancer cell
proliferation. Dihydrotestosterone (DHT)-bound androgen receptor (AR) complex can activate
two independent pathways—AR-dependent gene expression, such as prostate-specific antigen
(PSA), and AR-dependent cell proliferation, involving the p66Shc–reactive oxygen species
(ROS) pathway. Stimulation of androgenic proliferation includes an increase in p66Shc protein
level after DHT treatment. Increased p66Shc translocates into mitochondria, where it interacts
with cytochrome c (Cyt c), localized in the mitochondrial inner membrane, and generates ROS
production. Increased ROS production promotes cell cycle progression, through Cyclin D1
and, which in turn, increases cell proliferation. In addition to the activation of p66Shc–ROS
pathway, a part of the cell growth is also mediated by the genomic effects of the AR-dependent
pathway (Dotted arrow).
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